Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia
Gang EJ, Kim HN, Hsieh YT, Ruan Y, Ogana HA, Lee S, Pham J, Geng H, Park E, Klemm L, Willman CL, Carroll WL, Mittelman SD, Orgel E, Oberley MJ, Parekh C, Abdel-Azim H, Bhojwani D, Wayne AS, De Arcangelis A, Georges-Labouesse E, Wayner E, Bonig H, Minasyan A, ten Hoeve J, Graeber TG, Müschen M, Heisterkamp N, Kim YM. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood 2020, 136: 210-223. PMID: 32219444, PMCID: PMC7357190, DOI: 10.1182/blood.2019001417.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaDrug resistanceTyrosine kinase inhibitor treatmentIntegrin α6Minimal residual diseaseProteomic analysisAcute lymphoblastic B-cell leukemiaAdhesion-mediated drug resistanceKinase inhibitor treatmentNovel therapeutic targetConditional knockout modelCentral nervous systemSrc signalingB-cell leukemiaPhosphorylated LynCell adhesionVivo deletionKnockout modelsResidual diseaseLymphoblastic leukemiaKinase inhibitionTherapeutic targetNervous systemB cellsBCR-ABL1